| November 1, 2012 | ISSUE NUMBER 275 VOL 8 |
Video
Election 2012: Where's the Pharma Money Going?
Reid Paul presents Pharm Exec's latest video looking at what pharma is donating to the competing parties during this year's US election campaign ...Read more
Advertisement
Measurement of case quality in pharmacovigilance is a relatively new development. Until pharmaceutical companies began outsourcing their case processing operations, the only measure of effectiveness of their internal operations was compliance with regulatory reporting timelines. Now that these operations are performed by vendors, over the last two years vendor management organizations within pharmaceutical companies and Health Authorities have come up with a way to measure the “quality” of Adverse Event (AE) cases. This paper captures our experience and learning in defining and using  Case Quality Metrics while working with large and small pharmaceutical companies.
Contact Email:ask@sciformix.com |
Big Pharma
Merck, Novartis Down in Q3 Financial Reports
Pharmaceutical industry leaders Novartis and Merck—among others—released 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations
...Read More
Advertisement
2nd Annual Interactive Response Technologies for Clinical Trials
November 8-9, 2012 * Sonesta Hotel * Philadelphia, PA
Learn best practices in gaining insights into IVR/IWR system utilization in clinical trials and learn how companies are using clinical IRTs to increase efficiencies and decrease costs.
Register by November 7, 2012 at  www.cbinet.com/IRT and save $400 with priority code: FHZ888
|
Drug Approvals
Repositioned Drugs Surpass New Brands
It was in 1984 when FDA first added the 505(b)(2) pathway for drug approval, a hybrid between the accelerated pathway for generic drug applications, and the standard de novo NDA pathway for proprietary drugs. But in the past 6 years, approvals received through the 505(b)(2) pathway have consistently outnumbered de novo NDAs
...Read more
Advertisement
Brand: Going Beyond Single-Mindedness
Live Webcast: Thursday, November 8, 2012 from 2:00 PM - 3:00 PM EST
Register Free at  www.pharmexec.com/single |
Information to Patients
How Healthcare Analytics Can Improve the Patient Experience
Brad Sitler looks at the challenge for pharma of engaging patients and helping physicians provide them with the right information at the right time
...Read more
Advertisement
Measuring the impact of e-prescribing on practitioner behavior and promotional effectiveness
On Demand Webcast
Register Free at  www.pharmexec.com/eprescribing |
|
|
Advertisement
Next Generation Informatics Needs for Pharma
Live Webcast: Thursday, November 15, 2012 at 2:00 PM Eastern Time
Register Free at  www.pharmexec.com/informatics |
|
|
|
 // Eli Lilly announced that Melissa Barnes is to be promoted to Chief Ethics and Compliance Officer and Senior Vice President of Enterprise Risk Management. // Astellas named J. Patrick McCauley Jr as Regional Compliance Officer of the Americas. Mr McCauley will be based in the company’s new Northbrook, IL, headquarters. // Sir Christopher Gent, Chairman of GlaxoSmithKline, is to step down from the company’s Board. |
|
Advertisement
Engaging Oncology Providers: What Works?
Live Webcast: Wednesday, November 14, 2012 at 11:00 AM EST
Register Free at  www.pharmexec.com/whatworks |
|
|
|
|
|
 |
|
|
|
 |
|
 |
|
 |
2012 has been touted as a crucial year of the so-called patent cliff. Do you think the impact of patent expiries has been better or worse than expected?
|
|
|
|
